The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study

This publication has 14 references indexed in Scilit:

• Yttrium-90 DOTATOC: first clinical results
  European Journal of Nuclear Medicine and Molecular Imaging, 1999
• Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC.
  European Journal of Nuclear Medicine and Molecular Imaging, 1999
• Radiometal-Labelled Macrocyclic Chelator-Derivatised Somatostatin Analogue with Superb Tumour-Targeting Properties and Potential for Receptor-Mediated Internal Radiotherapy
  Chemistry – A European Journal, 1999
• The somatostatin receptor-targeted radiotherapeutic [ 90 Y-DOTA- d Phe 1 ,Tyr 3 ]octreotide ( 90 Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours
  European Journal of Nuclear Medicine and Molecular Imaging, 1998
• Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients.
  Gut, 1996
• Drug Therapy in Metastatic Neuroendocrine Tumors of the Gastroenteropancreatic System
  Published by Springer Nature ,1996
• Somatostatin-Receptor Imaging in the Localization of Endocrine Tumors
  New England Journal of Medicine, 1990
• LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATIN
  The Lancet, 1989
• Treatment of the Malignant Carcinoid Syndrome
  New England Journal of Medicine, 1986
• The glucagonoma syndrome: Surgically curable diabetes
  The American Journal of Surgery, 1979